For the roughly 180,000 Australians living with inflammatory bowel disease, remission has long carried a quiet uncertainty — the body feels well, yet the disease returns without warning. Researchers at the Walter and Eliza Hall Institute have now found a molecular reason for that uncertainty: intestinal cells in IBD patients remain primed to die even when symptoms have vanished, a smoldering defect that appears to drive the disease rather than merely follow from it. Studying nearly 900 biopsies and patient-grown mini-intestines, the team has begun to map what true remission might actually requ
Scientists discover hidden cellular defect that triggers IBD relapses even during remission
IBD affects approximately 180,000 Australians and causes serious symptoms including rectal bleeding, abdominal pain, diarrhea, fatigue, weight loss, and requires hospitalization during severe flare-ups.
Intestinal cells remain primed to die, even when patients feel well
Mark
So the study found this cell death problem even in people who feel fine. How does that square with what we call remission?
Mimi
It doesn't, really. Remission is defined by the absence of symptoms—no bleeding, no pain, no diarrhea. But the researchers found that at the molecular level, the intestinal cells are still in a vulnerable state, primed to die. The disease is quiet, but it's not gone.
Luke
Wait—they found this defect in some patients with well-controlled disease, but did they find it in all of them? The source says "some patients," which suggests variability.
Mimi
Right, there's variability. That's actually part of why this matters. Not every patient shows the same degree of this cell death signaling, and the ones with stronger signaling were more likely to relapse over the two-year follow-up.
Mark
So this could become a way to predict who's going to flare up?
Mimi
Potentially, yes. If you can measure this molecular marker in a patient's tissue, you might be able to identify who's at higher risk before symptoms return. That's the long-term goal.
Luke
But the source is clear that no diagnostic test or therapy is coming soon. This is foundational research. We don't yet know which of these molecular signals are actually actionable—which ones doctors could actually do something about.
Mimi
Exactly. They've identified the problem. Now comes the harder work of figuring out how to target it therapeutically.
Mark
Why is studying human tissue instead of mice so important here?
Mimi
Because IBD in mice doesn't accurately mimic the human disease. By working directly with patient biopsies and growing organoids from patient cells, they're studying the actual biology of human IBD, not a simplified model.
Luke
That's a real strength of the study. Nine hundred biopsies from eighty people is substantial. But it's still one institution's findings. We'll need replication and validation before this becomes standard clinical practice.
Mark
What happens next?
Mimi
More research to understand which of these molecular defects can be targeted with drugs, and whether identifying them in individual patients can actually change treatment decisions and outcomes.
The Pulse
- IBD patients who feel completely well may still carry an active molecular fault in their gut lining, quietly setting the stage for the next flare-up.
- Analysis of 900 biopsies revealed that abnormal cell death is not a consequence of inflammation but one of its earliest drivers — a finding that upends a foundational assumption about how the disease works.
- Patients with stronger cell death signaling in their intestinal tissue were measurably more likely to relapse over a two-year follow-up period, linking a molecular marker directly to future disease behavior.
- The discovery shifts research attention from the acute crisis of hospitalization toward the deceptively quiet periods in between, where the first dominoes of relapse are already falling.
- While a clinical test or new therapy remains years away, the findings lay groundwork for personalized monitoring — matching treatments to how each patient's disease behaves at the cellular level, not just the symptomatic one.
For the roughly 180,000 Australians living with inflammatory bowel disease, remission has long carried a quiet uncertainty — the body feels well, yet the disease returns without warning. Researchers at the Walter and Eliza Hall Institute have now found a molecular reason for that uncertainty: intestinal cells in IBD patients remain primed to die even when symptoms have vanished, a smoldering defect that appears to drive the disease rather than merely follow from it. Studying nearly 900 biopsies and patient-grown mini-intestines, the team has begun to map what true remission might actually require — not just the silencing of symptoms, but the resolution of something far deeper in the cellular machinery of the gut.
A patient sits in a doctor's office feeling well. Symptoms are gone, blood work is clean, and the disease appears controlled. But deep inside the intestinal lining, cells remain primed to die — waiting for a trigger. This hidden molecular defect, researchers have now identified, may explain why IBD so reliably returns even after long stretches of apparent calm.
Scientists at the Walter and Eliza Hall Institute, working alongside clinicians at the Royal Melbourne Hospital, analyzed roughly 900 intestinal biopsies from 80 people and grew patient-derived mini-intestines in the laboratory to study the disease in human tissue directly. What they found challenges a long-held assumption: the abnormal cell death they observed is not collateral damage from inflammation — it appears to be one of the disease's earliest drivers, present before symptoms emerge and detectable even in patients who feel completely fine.
Inflammatory bowel disease, encompassing Crohn's disease and ulcerative colitis, affects around 180,000 Australians and causes rectal bleeding, severe abdominal pain, diarrhea, fatigue, and weight loss. Modern treatments have brought many patients to remission, but the disease remains unpredictable. As Dr. Andre Samson put it, even symptom-free patients carry "this persistent problem sitting there" — intestinal cells still primed to collapse. The team tracked patients for over two years and found that stronger cell death signaling correlated with higher relapse risk, connecting a molecular signature to future disease behavior.
Professor James Murphy noted that most IBD research has focused on the acute crisis — the moment a patient arrives at hospital in severe distress. This study looked at the other end of the spectrum, at tissue with no obvious signs of active disease, and found the molecular fault already at work. Dr. Jiyi Pang framed the next challenge clearly: identifying which of these molecular hallmarks are therapeutically actionable and whether they can help match treatments to individual patients based on how their disease behaves beneath the surface.
The work signals a broader shift — from one-size-fits-all treatment toward personalized medicine grounded in molecular biology. A clinical tool may still be years away, but the discovery reframes what remission means: not an absence of disease, but perhaps a temporary truce with something that continues to smolder, unseen, in the cells of the gut.
A patient with inflammatory bowel disease sits in a doctor's office, feeling well. Blood work looks good. Symptoms have vanished. The disease appears to be in remission. But deep inside the intestinal lining, at the molecular level, something is still wrong—cells remain primed to die, waiting for the right trigger to collapse. This hidden defect, researchers have now discovered, may explain why so many IBD patients experience sudden, severe flare-ups even after months or years of feeling fine.
Scientists at the Walter and Eliza Hall Institute, working with clinicians at the Royal Melbourne Hospital, have identified what they call a "smoldering" molecular problem in the gut cells of people with inflammatory bowel disease. The finding emerged from an unusually rigorous study: the team analyzed roughly 900 intestinal biopsies taken from 80 people, some with IBD and some without, and grew patient-derived mini-intestines in the laboratory to study the disease directly in human tissue rather than relying on animal models. What they found challenges a long-held assumption about how IBD works. The abnormal cell death they observed is not simply collateral damage from inflammation—it appears to be a driver of the disease itself, present from the earliest stages of disease activity and detectable even in patients whose symptoms are completely controlled.
Inflammatory bowel disease, which includes Crohn's disease and ulcerative colitis, affects roughly 180,000 Australians. The condition causes rectal bleeding, severe abdominal pain, diarrhea, fatigue, and weight loss. Modern treatments have helped many patients reach remission, but the disease remains unpredictable. Patients cycle between periods of stability and sudden flare-ups severe enough to require hospitalization. Dr. Andre Samson, one of the study's authors, explained the paradox: "Once you've got the diagnosis, IBD doesn't go away. Even if you become symptom-free on the current treatments, we know there's a likelihood you're going to have a flare or relapse. What we found in patient samples was that intestinal cells are primed to die. Even in patients with essentially no symptoms, there's still this persistent problem sitting there."
The research team tracked patients for more than two years. They discovered that those showing stronger intestinal cell death signaling were more likely to experience a relapse. This connection between a molecular marker and future disease activity opens a new avenue for understanding why IBD behaves so differently from person to person. Professor James Murphy, a deputy director at WEHI, noted that most research has focused on the acute crisis—the moment a patient arrives at the hospital with severe gut inflammation. "We've gone to the other end of the spectrum and looked at gut tissue that doesn't have clear signs of active disease," he said. "What we're finding is this molecular defect happening very early in disease progression—one of the first dominoes to fall."
The implications are significant but not immediate. Dr. Aysha Al-Ani, another study author, cautioned that these findings are unlikely to produce a new diagnostic test or therapy in the near term. However, they provide a foundation for future work. The newly identified molecular signals could eventually help scientists develop more precise tools for monitoring individual patients and selecting treatments tailored to how each person's disease behaves at the cellular level. Dr. Jiyi Pang emphasized the variability of IBD: "The causes of IBD are largely unknown and quite variable. We now have the hallmarks of what underlies disease at the molecular level. The question is which of those are therapeutically actionable and whether they might help us to better match treatments to patients, based on how their disease behaves at a molecular level."
The work represents a shift in how researchers approach IBD—moving away from one-size-fits-all treatment toward personalized medicine grounded in molecular biology. If future research can translate these molecular markers into clinical tools, doctors may eventually be able to predict which patients are at highest risk of relapse and intervene before symptoms return. For now, the discovery simply reveals what has been hidden: that remission, as patients experience it, may not be remission at all, but rather a temporary truce with a disease that continues to smolder beneath the surface.
Notable Quotes
Even in patients with essentially no symptoms, there's still this persistent problem sitting there.— Dr. Andre Samson, study co-author
We've gone to the other end of the spectrum and looked at gut tissue that doesn't have clear signs of active disease. What we're finding is this molecular defect happening very early in disease progression.— Professor James Murphy, WEHI deputy director
Want the full story?
Read the original at ScienceDaily ↗
Health & Medicine